CRH Investors Logo

CRH Medical Announces Anticipated Revenue for the Year Ending December 31, 2013

VANCOUVER, January 10, 2014 – CRH Medical Corporation (TSX: CRH, OTCQX: CRMMF),
a North American medical company focused on providing physicians with innovative products
for the treatment of gastrointestinal diseases, today announced that it expects to report
revenue for the year ended December 31, 2013 of approximately US$7,680,000.

The anticipated revenue for the year ending December 31, 2013 would represent a 12 percent
increase compared to the year ending December 31, 2012. This announced revenue is a
preliminary, unaudited management assessment of revenue for the period.

“We are extremely excited about our fourth quarter, 2013 revenue results. For the first time in
the history of CRH, the Company recorded more than US$2,000,000 in quarterly revenue,” said
Edward Wright, Chief Executive Officer of CRH Medical. “The awareness of the CRH O’Regan
System, as well as the number of physicians using the CRH O’Regan System, continues to
increase across North America. This increase in physicians utilizing the CRH O’Regan System
has translated into higher annual revenue for CRH Medical. Looking ahead, we are optimistic
that we can continue to steadily grow our business.”

The O’Regan System is a single use, disposable, hemorrhoid treatment that is safe and highly
effective in treating hemorrhoid grades I – IV. The Company’s goal is to establish the O’Regan
System as the standard of care for hemorrhoid treatment. In addition to the product, CRH
Medical delivers clinical, marketing and operational support directly to its partner physicians.
CRH Medical intends to announce comprehensive 2013 year-end, audited results by March 31,

About CRH Medical Corporation:

CRH Medical Corporation specializes in the distribution of innovative medical products directly
to physicians, particularly those in the gastroenterologist community. The Company’s lead
product, the CRH O’Regan System, is a single use, disposable, hemorrhoid treatment that is
safe and highly effective in treating hemorrhoid grades I – IV. The O’Regan System is rapidly
emerging as the standard of care with gastroenterologists who treat hemorrhoids. In addition to
the product, CRH Medical delivers clinical, marketing and operational support directly to its
partner physicians. CRH utilizes its web-based platform to connect doctors with patients as well
as educating its ever increasing install base of physicians.

For more information, please contact:

Edward Wright, Chief Executive Officer
CRH Medical Corporation
604.633.1440 x1008


Adam Peeler, Media and Investor Relations
TMX Equicom
416.815.0700 x 225

Forward looking statements:

The information in this news release contains so-called “forward-looking” statements. These
include statements regarding anticipated revenue and future growth of our business as well as
statements regarding CRH Medical’s expectations and plans relating to its business, statements
about CRH Medical’s expectations, beliefs, intentions or strategies for the future, which may be
indicated by words or phrases such as “anticipate”, “expect”, “intend”, “plan”, “will”, “we
believe”, “CRH Medical believes”, “management believes”, and similar language. All forwardlooking
statements are based on CRH Medical’s current expectations and are subject to risks
and uncertainties and to assumptions made. Assumptions include: (i) that the growth of CRH’s
product sales will continue in a consistent manner; (ii) CRH’s costs will not escalate significantly; and (iii) CRH does not incur any extraordinary costs.

Important risk factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) we may not continue to attract
Gastroenterologists and other licensed providers to purchase and use the CRH O’Regan
System; (ii) the policies of health insurance carriers in the United States may affect the amount
of revenue the Company receives; (iii) changes in United States federal or state laws, rules, and
regulations; (iv) our senior management has been key to our growth, and we may be adversely
affected if we lose any member of our senior management; (v) Our Clinical Sales
Representatives may not be able to increase adoption of the CRH O’Regan System; (vi)
economic dependence on suppliers and our contract manufacturer; (vii) changes in the industry
and the economy may affect the Company’s business; (viii) evolving regulation of corporate
governance and public disclosure may result in additional corporate expenses; (ix) we may be
subject to competition and technological risk which may impact the price and amount of product
we can sell; (x) we may be subject to product liability which may adversely affect our operations;
(xi) we may need to raise additional capital to fund future operations; (xii) our business may be
impacted by health care reform in the United States; (xiii) we may not have the expertise
required to expand internationally. As a single product company, any adverse event directly or
indirectly related to the CRH O’Regan System will have a material impact on the Company’s
financial performance. CRH Medical bases its forward-looking statements on information
currently available to it, and assumes no obligation to update them, except as required by law